Werewolf Therapeutics, Inc.

HOWL Healthcare Biotechnology

Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.

0.98 0.02 −2.00%
Market cap
$48.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
3/9
Altman Z
−4.83
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(122.43%) (123.88%) (161.89%) (119.86%)
ROA
(66.32%) (61.96%) (68.09%) (59.31%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(130.87%) (224.22%) (387.90%) (212.45%)
Average Days of Receivables
— — — 0.00
Free Cash Flow per Share
(1.39) (1.31) (1.07) (0.61)
Free Cash Flow
(63.52) (60.29) (51.94) (29.87)
Capital Expenditures
— — — 0.27
Other line items
Cash ROIC
(54.30%) (73.66%) (88.56%) (78.05%)
Accounts Receivable Turnover
— — — 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 134.95%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 79.34%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 15.56%
Interest Coverage
(13.85) (11.50) (10.40) (6.87)
Operating CF/Net income
0.87 0.99 0.92 0.87
Depreciation/Fixed assets
0.33 0.35 0.37 2.89
Capex/Depreciation
0.00 0.00 0.00 0.07
Revenue per Share
0.00 0.00 0.00 0.50
Operating CF per Share
(1.39) (1.31) (1.07) (0.62)
Capex per Share
0.00 0.00 0.00 0.01
Capex to Sales
— — — (0.01)

Fold the line items

Columns are period end dates